All In Biotech

NDA 022083 · Sandoz

Exelon

Rivastigmine · Transdermal · Cholinesterase Inhibitor

Last checked: Nov 20, 2026Latest source record: May 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jul 6, 2007

Approved uses

3

Original approval plus efficacy supplements

Registered trials

100

26 Phase 3, 4 recruiting

FAERS reports

18,807

16,024 serious, 4,787 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 8, 2024.

EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). ( 1.1 ) • Mild-to-moderate dementia associated with Parkinson’s disease (PD). ( 1.2 ) 1.1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 1.2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PDD).

Mechanism: Although the precise mechanism of action of rivastigmine is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that rivastigmine alters the course of the underlying dementing process.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • EXELON · RIVASTIGMINE 9.5MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • EXELON · RIVASTIGMINE 13.3MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • EXELON · RIVASTIGMINE 4.6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rivastigmine" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death2,337
  • fall1,791
  • hallucination1,475
  • confusional state1,331
  • drug ineffective957
  • vomiting909
  • nausea858
  • dizziness811
  • gait disturbance751
  • pneumonia728
  • somnolence692
  • fatigue681

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004323
2005236
2006201
2007226
2008611
2009904
2010943
20111,364
20121,451
2013411
2014611
2015673
2016941
2017944
2018984
2019841
20201,048
2021906
2022936
2023952
20241,009
20251,310
2026977

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Exelon (Rivastigmine)

2024 spending

$10.4M

Beneficiaries

2,813

12,602 claims

Per beneficiary

$3,710

$22.66 per unit

View as table
YearSpending
2020$58,031,637
2021$37,741,853
2022$25,954,523
2023$19,709,214
2024$10,434,913

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 417 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.